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Abstract 
 
 
The vast diversity of S100 proteins has demonstrated a multitude of biological correlations 
with cell growth, cell differentiation and cell survival in numerous physiological and 
pathological conditions in all cells of the body. This review summarises some of the reported 
regulatory functions of S100 proteins (namely S100A1, S100A2, S100A4, S100A6, S100A7, 
S100A8/S100A9, S100A10, S100A11, S100A12, S100B and S100P) on cellular migration 
and invasion, established both in culture and in animal model systems and the possible 
mechanisms that have been proposed to be responsible. These mechanisms involve 
intracellular events and components of the cytoskeletal organisation (actin/myosin filaments, 
intermediate filaments and microtubules) as well as extracellular signalling at different cell 
surface receptors (RAGE and integrins). Finally we shall attempt to demonstrate how 
aberrant expression of the S100 proteins may lead to pathological events and human 
disorders and furthermore provide a rationale to explain possibly why the expression of some 
of the S100 proteins (mainly S100A4 and S100P) have led to conflicting results on motility, 
depending on the cells used.       
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1. Introduction 
 
Since their initial discovery half a century ago [1] as a group of low molecular weight acidic 
polypeptides (10 to 12kDa), the identification of new members of the family of S100 proteins 
has been gathering momentum. To date, approximately 25 different proteins have been 
assigned to the family which consists of 16 S100A proteins (S100A1-S100A16) as well as 
others (such as S100B, S100G, S100P and S100Z). These proteins exist as monomers (only 
calbindin is stable in this configuration), homo-, heterodimers or multimeric forms within 
cells and their extracellular matrices [2]. Their sequence identity data overall ranges from 16 
to 98% with S100A3 and S100A7 having the lowest conserved identity and similarity (16% 
and 28%, respectively), whereas S100A7 and S100A15 share 95% of identical or similar 
sequences (Table 1). This high degree of similarity between the protein paralogues, averaging 
around 50% when looking across all the different members, is thought to be due to several 
rounds of gene duplication events during evolution [3]. Consequently, the genes encoding the 
majority of the S100 proteins (S100A1-S100A16) are clustered at the chromosomal locus, 
1q21, into two subgroups, with S100A10 and S100A11 tightly linked in one chromosomal 
location and the remaining chromosme 1-members (S100A1-9 and S100A12-16) in another 
[4].  The genes encoding the remaining known S100 proteins, S100B, S100G, S100P or 
S100Z, are found on chromosomes 21, X, 4 and 5, respectively.  
 
A feature common to all of these proteins is the presence of a pair of calcium-binding 
helix-loop-helix domains referred to as EF-hand calcium-binding regions towards either end 
of the protein and separated by a hinge region [5]. The C-terminal EF-hand motif, composed 
of 12 amino acids is a canonical calcium-binding domain and possesses a calcium affinity 
which is 10-50 times higher (Kd between 10 - 50M) than that of the N-terminal loop [6-8], a 
14 amino-acid long domain considered to be more S100 specific in its composition (referred 
to as S100 specific or pseudo EF-hand). The two calcium-binding motifs demonstrate the 
highest levels of amino acid conservation throughout the S100 proteins (Fig. 1). When 
considering the canonical EF-hand motif, amino acids at positions 1, 3, 5, 10 and 12 are 
essential for the formation of the calcium-binding loop [9] forming the consensus sequence 
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D1XN3XD5XXXXF10XE12. This arrangement is found conserved in all S100 proteins, except 
for S100A10, S100A14 and S100B, where the observed sequences are 
D1XC3XD5XXXXF10XS12, G1XC3XD5XXXXF10XS12 and D1XD3XD5XXXXF10XE12, 
respectively. The mutations and/or deletions of key residues result in the inactivation of the 
EF-hand motifs and the loss of their ability to bind Ca
2+
, at least for S100A10 [10] and 
S100A14 [11]. The sequence of the pseudo EF-hand motifs shows that they are also highly 
conserved amongst the various human S100 proteins (Fig. 1). However, there is less 
stringency and identity than for the canonical loop, since  Ca
2+
 binding to this motif is mostly 
accomplished through main-chain carbonyl groups, resulting in a weaker affinity for Ca
2+ 
and 
a Kd of around 200-500M [6]. 
Binding of calcium to these motifs, whenever possible, results in a conformational 
change that exposes a hydrophobic region of the proteins [12]. This amphipathic patch is 
predicted in the hinge region (Fig. 1) and the C-terminal portion of the S100 proteins [13,14].  
Not surprisingly, these two regions show the least amount of sequence homology, perhaps 
highlighting their importance and specificity in binding to target molecules. It is through 
these interactions that the S100 proteins modulate the activity of other cellular components 
both intracellularly and extracellularly, since they themselves contain no intrinsic enzymatic 
activity. Sequence analysis also demonstrates that all S100 proteins lack the typical leader 
sequences required for endoplasmic reticulum entry and are consequently externalised 
independently of the orthodox endoplasmic reticulum and Golgi complex secretory route. 
Amongst the S100 proteins, the role of S100A13 in the non-classical secretory pathway is the 
best described, forming well characterised stress-dependent multimeric complexes with 
specific cytokines such as interleukin 1a and fibroblast growth factor 1 (FGF) (for example 
see [15]). However, the exact mechanisms in place to facilitate the release of S100 proteins 
generally remain unclear, but seem to require proper microtubule and actin cytoskeletal 
organisation, at least for some of the factors  [16,17]. 
Because of the diversity of S100 proteins, and because they can regulate protein 
activities, both intracellularly as well as in extracellular spaces, a plethora of binding partners, 
and as a consequence many biological pathways, have been suggested to be affected by these 
proteins. Whilst there is some evidence that the presence of S100 proteins are associated with 
cell growth, division and differentiation (elegantly outlined in previous reviews [18-24] and 
some of the more recent contributions demonstrating such effects are summarised in Table 2), 
the presence of S100 proteins has been frequently associated with altered cell migration.  
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Thus, this review will focus on the reported regulatory functions of S100 proteins on cellular 
migration and cellular invasion, established both through cell culture work and in animal 
model systems, on a case by case basis. We shall present how, sometimes, contradictory roles 
of specific S100 proteins on cellular migration have been reported, possibly underlined by 
their presence as both cytoplasmic and/or extracellular pools (Table 3). We shall also 
summarise some of the possible mechanisms that have been proposed as potential regulators 
of such processes, including the targeting of cytoskeletal elements and provide a reflective 
rationale that could begin to explain the conflicting roles reported, on occasion, in different 
cell systems. Finally, through this work, we shall demonstrate how they regulate 
physiological processes and how, through aberrant expressions, they can also lead to 
pathological events and human disorders.       
 
 
 
 
 
2. S100 proteins and their effects on cell migration 
 
 
S100A1  
S100A1 was, along with S100B, the earliest discovered member of the S100 proteins [25,26]. 
It is expressed in numerous tissues in the human body, but is specifically found at high 
concentration (micrograms/mg of soluble protein) in cardiac/skeletal muscle and brain [27].  
Aberrant expression of S100A1 in these organs has been correlated with, but not necessarily 
causally, to pathological onsets, providing a new focus of therapeutic research to treat 
potentially neurological, heart and vascular disorders as well as diabetes mellitus and some 
types of cancer; these interactions are mainly intracellular (recently reviewed in Wright et 
al.[28]).  
 Loss of S100A1 expression in knockout mice in vivo has indicated that the animals do 
not suffer severe pathologies, but suggest a possible involvement for S100A1 in heart 
contractibility [29]. The same group has recently also proposed a function for S100A1 as an 
angiogenesis agent. Indeed S100A1 genetically ablated mice were found to present 
insufficient perfusion recovery following femoral artery resections [30]. S100A1 knockout 
endothelial cells isolated from the same animals demonstrated an impaired migration during 
scratch wound assay, suggesting that intracellular S100A1 may possess some motility-
promoting effects in these cells. Altering levels of S100A1 in breast epithelial tumor cells 
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has, however, been shown to result in no apparent changes in migratory/invasive properties 
[31].  
Whilst, as described above, the direct evidence of S100A1 in cellular motility, 
particularly in vivo, has been rather scarce, the reports of its expression on cytoskeletal 
structural remodelling have been numerous in vitro. Loss of S100A1 can regulate positively 
the levels of tubulin in rat pheochromocytoma cells, leading to an increase in neurite 
formation [32], whilst in astrocytes, addition of recombinant S100A1 resulted in the calcium-
dependent disassembly of Triton-insoluble microtubular structures in vitro [33]. Consistent 
with these findings, purified S100A1 protein has been reported to inhibit microtubule 
assembly in a Ca
2+
 and pH dependent manner [6,34], where the C-terminal part of the protein 
is essential for their interactions [35]. Other cytoskeletal components of the intermediate 
filaments can also interact with S100A1 (reviewed in Garbuglia et al.[36]). Direct interaction 
with desmin, for instance, has been highlighted, resulting in the inhibition of desmin 
intermediate filaments [37].  
 Finally, interactions of intracellular S100A1 with the microfilaments have also been 
demonstrated in different cell types in culture. For instance, in the more specialised 
filamentous actin (F-actin) structure of the sarcomere, the formation of the titin-F-actin 
complex can be inhibited by S100A1 [38,39]. S100A1 can bind directly to the spring motif 
PEVK ((P)Proline,  (E) glutamic acid, (V) valine, and (K) lysine) of the cardiac specific N2B 
titin variant both in vitro and in situ. Such interaction competes for the binding of titin to F-
actin, resulting in the alleviation of the PEVK-based inhibition of the F-actin sliding 
mechanism. This competitive interaction, if proven at the organ level, may result in a 
significant reduction of passive tension during stretching of mouse left ventricular 
myocardium, providing another possible molecular explanation for the involvement of 
S100A1 in both cardiomyopathy and hypertrophy (reviewed in Ritterhoff and Most [40]). 
The association of intracellular S100A1 with F-actin has also been documented in 
other cell systems, since both proteins could be seen colocalised on stress fibers in cultured 
vascular smooth muscle cells in vitro and a direct interaction, using purified proteins, was 
further indicated by co-sedimentation analysis in vitro [41]. Equally important are the 
regulatory effects of S100A1 on F-actin polymerisation. S100A1 has been reported to interact 
with Synapsin I, preventing its dimerisation and resulting in the synapsin I-dependent F-actin 
assembly [42]. 
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All in all, S100A1 interactions with the various cytoskeletal components have now 
been well characterised. However, the physiological and biological consequences of such 
binding, at least in non-muscle cells, remain elusive. 
 
S100A2 
Initial findings suggested, maybe too enthusiastically, that expression of S100A2 was 
typically down regulated in tumors relative to normal tissue and consequently it may act as 
a tumor suppressor gene.  The first series of reports implicating S100A2 in cellular motility 
came from work on human squamous carcinoma cell lines [43,44], where reduction in the 
levels of S100A2 mRNA by antisense technology increased cellular motility, whilst 
addition of exogenous extracellular S100A2 to the medium in the nanomolar range, or 
intracellular ectopic expression resulted in reduced rates of migration, implicating that both 
intracellular and extracellular pools of the proteins may influence cell motility. The 
biological explanations have not been unequivocally established, but initial experiments in 
these reports provided possible mechanisms to explain such observation. Thus, effects on 
cellular migration may be due to changes in the polymerisation dynamics of the actin 
filaments as well as a possible involvement of the receptor for advanced glycation end 
product (RAGE), a trans-membrane protein belonging to the immunoglobulin family [43].  
Forced overexpression of S100A2 in squamous cell carcinoma cells in vitro has 
been linked to differential expression of numerous genes, some of which are involved in 
cytoskeletal organisation and migration [44], for example reduced level of the 
inflammatory-associated, cyclooxygenase-2 (Cox-2). Re-expression of Cox-2 protein in 
S100A2-expressing cells partially reversed S100A2- dependent loss of invasion and 
growth in soft agar [44].  
 The concept of S100A2 as a tumor suppressor gene has, however, since been 
challenged by more recent reports which have also highlighted its aberrant overexpression 
as an essential step towards tumorigenesis and metastasis in experimental cell systems [45] 
(reviewed in Wolf et al. [46]).  Studies aiming to determine the biological consequences of 
its intracellular expression in different human carcinomas highlight both its cytoplasmic 
and nuclear location [47] and its interaction with p53 and its p67 and p77 orthologs, at least 
in vitro [48,49], thereby providing a possible model to regulate the intracellular functions 
of the p53 family proteins in growth arrest and apoptosis.  
S100A2 expression has also been linked to enhanced chemotaxis and cellular 
migration and invasiveness in both physiological and pathophysiological conditions. As 
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early as 1996, the presence of extracellular S100A2 in the medium of eosinophils was 
shown to promote chemotaxis over a wide range of doses between 10
-10 
to 10
-5
M [50].  
Forced overexpression of intracellular S100A2 in stably transfected, non-small cell lung 
cancer cell lines can also result in enhanced migratory and invasive properties using 
transwell and trans-endothelial assays [51,52]. More importantly, high expression of 
intracellular S100A2 in non-small cell lung cell lines promoted their metastasis in vivo 
[51]. Concomitant with a role in invasion, reducing the levels of intracellular S100A2 
through the use of short hairpin RNA (shRNA) in these same cells was also sufficient to 
prevent any further spreading of the tumor cells from the initial lesion [51]. Transforming 
growth factor- (TGF-)-induced motility and invasion of hepatocellular carcinoma cell 
lines were significantly reduced when intracellular levels of S100A2 were knocked down 
using specific shRNA and small interfering RNA (siRNA) technologies [53]. Further 
analysis of the data indicates that the impairment in migration and invasive abilities were 
also seen without treatment with TGF- (Discussion with Kondaiah P. and Naz S.), 
demonstrating a direct role of intracellular S100A2 in motility at least in vitro. 
 Biological mechanisms to explain the conflicting effects of S100A2 on cell motility 
and invasion in different cell systems are still missing.  Unfortunately, only limited direct 
links between S100A2 and components of the motility apparatus have so far been reported. 
Interactions of S100A2 with tropomyosin have been demonstrated in vitro and appear to be 
Ca
2+
 dependent. Colocalisation of intracellular S100A2 protein with the actin cytoskeleton 
has only been reported in the microvilli region of the kidney epithelial LLC PK1 cells grown 
to high density [54]. 
 In contrast S100A2 has been shown recently to interact with the cell surface receptor, 
RAGE, with a Kd in the micromolar range using surface plasmon resonance experiments 
with recombinant GST-RAGE proteins [55]. However, a direct correlation between their 
interactions and any changes in cellular motility remain to be demonstrated, providing no 
direct route to explain any relationship between the level of extracellular S100A2 and cellular 
migration.  Thus overall, the links between S100A2 levels and cell migration appear 
contradictory in various cell systems and lack a consistent molecular explanation. 
 
 
S100A4 
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Originally named mts1, 18A2, CAPL, FSP1, Metastatin, p9Ka, PEL98, 42A, Calvasculin and 
Placental Calcium Binding Protein, S100A4 is one of the S100 proteins that has received 
constant attention in the field of carcinogenesis, due to its significant role in directly 
promoting the metastatic process, first established by us in 1993 [56](see review Mishra et al. 
[57]). Indeed, since our original results [58], S100A4 has now been confirmed to be a very 
potent marker for cancer prognosis, acting as a predictor for poor outcome [59] particularly in 
high risk patient groups [60]. Consequently, the biological functions of S100A4 have 
primarily been studied in cancer systems, whether cellular or animal. S100A4 expression can 
provoke increased motility and invasion in cancer cell lines originating from breast, 
colorectal, pancreatic, lung and esophageal squamous epithelia to list just a few recently 
published contributions [61-69].  
In non-cancerous tissues, S100A4’s presence intracellularly, is increased in human 
endometriosis, a pathological condition in which endometrial tissue migrates to ectopic sites 
[70]. Similarly, expression of intracellular S100A4 protein is also seen in cells of the stromal 
compartment of the normal mammary gland of adult humans and during active ductal 
development, possibly acting as one of the mediators of mammary gland development [71], 
where it was originally discovered as a marker of epithelial to mesenchymal differentiation 
towards a myoepithelial-like phenotype [72]. Experimentally S100A4 was shown to increase 
the invasion of epithelial cells into the fat pad during branching morphogenesis in vivo in a 
TGF-α mediated pathway, possibly through the regulation of levels of matrix 
metalloproteinase (MMP)-3 and E-cadherin [73].  
In other non-disease states, high levels of the intracellular protein and/or mRNAs are 
primarily found in motile cells in vivo, such as those of the immune system (peritoneal 
macrophages, neutrophils and human lymphocytes  [74-76] as well as mesenchymal 
fibroblastic cells [77,74]). The true biological consequences of S100A4’s presence in normal 
physiological processes remain to be fully characterised, since mice overexpressing [78] or 
lacking the expression of S100A4 [79] do not exhibit overt abnormalities compared to wild-
type animals.  It was only when the increased level of S100A4 expression occurred in the 
presence of a coupled oncogene product that gross pathologies were observed [80]. With 
more scrutiny, however, some changes in cellular motility have now been reported, both in 
vitro and more importantly in vivo, when studying different cell types and tissues. When 
intracellular S100A4 is depleted, macrophages are significantly impaired in their ability to 
reach sites of inflammation in mice, whilst bone marrow macrophages isolated from the same 
animals possess a reduced chemotactic motility in vitro [81].  At the cellular level, loss of 
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intracellular S100A4 expression resulted in severe loss of lamellipodia stability and 
pronounced random migration, suggestive of defects in cell polarisation [81]. Such 
observations identify the S100A4 protein as an important intracellular agent capable of 
regulating cellular migration in physiological conditions. Intracellular S100A4’s ability to 
regulate cell migration in vitro has been further supported by work on renal proximal tubular 
epithelial cells in culture, where altered levels of S100A4 forced either by stable transfection 
or epidermal growth factor (EGF) and TGF-1 stimulation led to a more mesenchymal 
fibroblastic morphology [82,83]; repressing its intracellular expression using antisense 
technology following EGF and TGF-1 treatments were sufficient to repress these 
phenotypes [83].  
Again phenotypic similarities have been observed in cancer cells. Our original work 
[56], confirmed by others [84,83,85], showed that overexpression of intracellular S100A4 in 
tumor cells in vitro leads to severe changes in cell architectures to a more mesenchymal type 
signature. Changes in motility protrusions and overall organisation of actin were also 
observed, with a large number of lamellipodial extensions and forward protrusions at the cell 
front [86,61].   
 S100A4 is found primarily intracellularly, at a concentration as high as 10 M [87], 
with no specific sub-localisation, being observed both in the cytoplasm and in the nucleus. 
Traces of the protein have also been detected in the extracellular space, both in culture 
[17,88], in tumor interstitial fluids [89] and in the serum of ageing mice [90]. The biological 
functions of externalised S100A4 are unknown at present, but initial experiments suggest that 
addition of recombinant S100A4 (in the micromolar range) in the extracellular environment 
is sufficient to promote cellular migration, at least in vitro. Enhanced motility was therefore 
seen in endothelial cells [90], in human pulmonary artery smooth muscle cells [91,92] and in 
T-lymphocytes and fibroblasts [17,93]. In such instances, S100A4 is thought to promote 
these activities through either the secretion and activation of MMP, such as MMP-13 [94], 
and/or possibly through regulation of the activities of specific cellular receptors such as 
annexin 2/plasmin [88], RAGE [91,92] or possibly fibronectin deposition [17]. 
 It is important to note, however, that not all cell types appear to respond in a similar 
manner to S100A4. Elevated concentrations of intracellular S100A4 protein have been shown 
to be inhibitory for cellular migration in astrocytes and that lowering its intracellular level 
through siRNA is sufficient to promote their migration, where MMP-9 and MT1-MMP may 
be involved [95]. This work was further supported by the fact that down regulation of 
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S100A4, either through siRNA treatment in astrocyte cultures, or in S100A4 knockout 
transgenic mice, was sufficient to promote cellular migration in response to injury, resulting 
in a reduction in glial scar formation in animals [96].  This potential pathophysiologic role of 
S100A4 in the central nervous system has recently been challenged. Indeed high expression 
of S100A4 by astrocytes has now been demonstrated in response to traumatic brain injury (in 
both human and rodent systems) and brain excitotoxicity. Such trauma resulted in the 
subsequent release of S100A4 from these cells into the extracellular environment, inducing 
neuroprotective effects, possibly through the regulation of metallothionein I and II [97]. The 
exact mechanisms leading to such protective functions remain to be fully elucidated, but 
initial experiments indicated the presence of two neurotrophic motifs on S100A4 which 
resulted in the activation of the Janus kinase/STAT pathway to prevent neurodegeneration 
[97].  
 Overall the direct molecular pathways that are responsible for the regulation of 
cellular motility remain to be fully characterised, since numerous pathways have now been 
suggested to regulate such a property (above remarks and herein). S100A4 has been shown to 
interact with proteins involved in the cytoskeletal architecture which may be a possible link 
with motility. Indeed S100A4 has been reported to bind directly to tropomyosin [98] and to 
F-actin [99,100]. The direct biological consequences of such interactions still remain to be 
elucidated in vivo, since other studies have demonstrated much lower binding affinities using 
biometric analysis in the case of tropomyosin [101].  
 More recently intracellular S100A4 was shown to interact with the Rho binding and 
regulating protein, Rhotekin, through pull-down and immunoprecipitation experiments [102] 
in a complex where RhoA was also present. These proteins have been intimately linked with 
cell polarity and migration [103-107]. Reduced expression of intracellular S100A4 or 
Rhotekin by targeted knockdown led to diminished invasion and migration of MDAMB231 
breast cancer cells through an increase in contractile F-actin stress fibers. This new finding 
suggests that intracellular S100A4 and Rhotekin possibly share a cooperative signalling event 
resulting in the regulation of the RhoA pathway, at least in cultured cells.  
 The cytoskeletal complex with which intracellular S100A4 interacts that has received 
most interest is undoubtedly the non-muscle myosin (NM) heavy chains [108-110,101]. The 
NM heavy chains, stabilised by the essential light chains and controlled by the regulatory 
light chains, form fully functional myosin structures present in all non-muscle eukaryotic 
cells. They play essential roles in cellular processes where force generation and movement 
are required. Among others, the NM composed of the isoforms IIA, IIB and IIC (NMIIA, 
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NMIIB and NMIIC) are seen as crucial components of cell polarity and migration, 
participating in the remodelling of the actin cytoskeleton [111,112].  Whereas NMIIA force 
generation is responsible, at least in part, for the assembly of the actomyosin network in 
cellular protrusions and the dynamics of adhesion, NMIIB establishes front to back cellular 
polarity through the cross-linking of actin filaments in cultured cells [113,114]. Analysis at 
the biochemical level and using recombinant proteins indicates that S100A4 preferentially 
binds to and inhibits the assembly of NMIIA filaments, but has little effect on NMIIB 
organisation [108]. This specific intracellular interaction has been confirmed by fluorescence 
lifetime imaging microscopy in cultured cells [115]. Consistent with such observation, 
absence of intracellular S100A4 leads to an over-assembly of NMIIA complexes in cultured 
bone marrow macrophages, possibly leading to the instability of the different cellular 
protrusions formed [81]. Moreover overexpression of intracellular S100A4 in breast 
carcinoma cell lines results in large cellular lamellipodia formed at the leading edge, but a 
general loss of filopodial extensions and focal adhesion assembly and maturation [61]. These 
latter effects may indeed be due to the ability of intracellular S100A4 to interact with NMIIA, 
since the expression of a truncated form of the protein, which prevents its binding to NMIIA 
[116,117], leads to loss of filopodial extensions and assembled focal adhesions. The resulting 
mechanisms are still not entirely clear [87], but it is logical to suggest that, since intracellular 
S100A4 is thought to affect NMIIA disassembly by binding to the unstructured NMIIA tail 
[118,110,119], its absence may lead to an over-assembled network of NMIIA [81], whilst its 
intracellular overexpression and binding may prevent and even unzip the overall organisation 
of NMIIA filaments [118]. 
 It is also important to note that the motility-promoting effects of S100A4 might not be 
exclusively due to direct regulation of the cytoskeleton architecture.  Evidence of a more 
general regulatory function have come to light recently demonstrating the involvement of the 
AKT/slug pathways in S100A4 mediated cell migration [67], where specific down regulation 
of intracellular S100A4 in esophageal squamous cell carcinoma resulted in low activity of 
AKT, low expression of the transcription factor slug and in parallel an increase in E-cadherin 
levels. Loss of E-cadherin and activation of slug transcription factor are seen as hallmarks of 
epithelial mesenchymal transition [120]. The inverse association between S100A4 and E-
cadherin expression is not novel and has been described in carcinoma cell lines [121], but the 
demonstration that such effects may be regulated through AKT activation is new. Other S100 
proteins have been shown equally to regulate AKT activity, as part of a more complex 
signalling cascade [122-124].  
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 The Wnt/-catenin pathway is also associated with S100A4-mediated cell migration 
[68], where the presence of a T cell factor (TCF) binding site in the 5’-untranslated region of 
the S100A4 promoter has been identified. Furthermore, -catenin has been shown to bind to 
this region and consequently increase the expression of the intracellular S100A4 protein, 
resulting in subsequent enhanced migration and invasion of colon carcinoma cells [125]. This 
regulatory mechanism has recently been utilised to isolate drugs that might ultimately lead to 
the reduction of S100A4 expression, namely calcimycin [68] and sundilac [126], possibly 
through regulation of the -catenin pathway; these have been shown to have potential 
therapeutic effects on colon carcinogenesis.  
 
 
S100A6 
The role of S100A6 protein (calcyclin) has been linked to changes in cellular motility and 
cytoskeletal reorganisation, but obtaining a clear picture has been challenging to ascertain, 
since its expression seems to lead to cell-specific as well as different in vivo/in vitro 
phenotypes. The most consistent results reported that when NIH-3T3 fibroblastic cells were 
forced to express low levels of intracellular S100A6 by knockout technology, there was a 
vast reorganisation of the actin cytoskeleton with an extensive cortical network of actin 
filaments and tropomyosin structures [127,128]. In parallel, the number of focal adhesions 
was seen to be significantly increased at the cell periphery, as determined by 
immunofluorescent staining for vinculin. These factors, may, therefore, be responsible at 
least in part, for the large increase in lamellipodia and possibly for the enhancement in 
cellular motility seen when intracellular S100A6 levels are knocked down [127].  
The involvement of S100A6 in the motility of cancer cells has also been reported, albeit with 
contradictory outcomes. Manipulating intracellular S100A6 levels in osteosarcoma cells, 
either by down-regulating or up-regulating its expression, led to increased or decreased 
migration, respectively, as measured by the wound healing assay, further suggesting a role for 
S100A6 as an inhibitor of cell motility in cultured cells [129,130].  
 However, S100A6 has also been shown to promote cellular motility in pancreatic 
cancer cells. Thus, reduction of its normally upregulated intracellular levels in this type of 
cultured tumorigenic cell leads to a reduction in their migration and lower invasive properties 
[131,132] by a mechanism that is dependent on the presence of annexin 2. Such data is 
supported by other correlative experiments performed on animals and tissues, where elevated 
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levels of intracellular S100A6 have been shown to be associated with tumorigenesis 
(reviewed in Lesniak et al. [133]) and the ability of colorectal adenocarcinoma cells [134] 
and Ras transformed NIH 3T3 cells [135] to metastasize to form secondary lesions.  
 The molecular mechanisms utilised by S100A6 to regulate cell motility have 
remained elusive. Direct interaction between S100A6 and the tropomyosin-actin complex has 
been shown in vitro following cross-linking experiments [136], but remains to be confirmed 
in vivo, since the only current evidence seems to suggest that S100A6 acts as a down-
regulator of tropomyosin expression [132]. Given the current uncertainties as to the role of 
tropomyosin in cellular motility [137], a direct correlation between their interactions and 
migratory properties is no more than conjecture. Other components of the actin cytoskeletal 
architecture, in the form of the myosin ATPase inhibitors, caldesmon [138,139] and calponin 
[140] can also interact with S100A6 in vitro, but no mechanistic link to cell motility has been 
demonstrated.  
 
 
S100A7 
S100A7 (psoriasin) is regarded as an inflammation-associated protein and to have 
chemoattractant properties, promoting migration of granulocytes, monocytes, macrophages  
and lymphocytes in vitro in the Boyden chamber assay, when added extracellularly at 
nanomolar concentration or if present in conditioned media [141,142]. Its action on 
enhancing cellular motility in vitro has also been reported in other non-hematopoietic cells as 
well as cells from pathophysiological conditions such as osteosarcoma, oral squamous and 
breast carcinoma [143-148]. It is currently unclear where S100A7 is located in these cells and 
the molecular pathways required.  In some cases, these results suggest a role for the 
extracellular pool of S100A7 promoting cell migration, at least in vitro. Indeed an increase in 
cellular motility could be reduced by addition of an antibody to S100A7 in the culture 
medium and was dependent on the RAGE receptor, since abrogating the receptor function 
using antibodies directed against it or by specific siRNA down-regulating the RAGE receptor 
resulted in suppressed migration and chemo-attraction [141,143,144].  
 In contrast, intracellular S100A7 can also interact with the multifunctional c-jun 
activation domain binding protein 1(Jab1) in human breast cancer cell lines [145]. 
Interestingly, the expression of a triple mutated form of the S100A7 protein in breast 
MDAMB231 cells that is unable to interact with Jab1, but has retained its ability to form 
dimers, demonstrated reduced ability to induce cellular migration, suggesting that the 
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intracellular S100A7-Jab1 interaction may play a role in such an event in vitro [147]. Another 
intracellular binding partner for S100A7 is the integrin subunit β6 identified through a 
proteomic approach using the β6 subunit cytoplasmic tail as bait. Immunostaining 
strengthens the case for a possible interaction between these two molecules, since they were 
seen to colocalise at the cell membrane and in intracellular vesicles in cultured cells [146]. 
Such interaction may also play some role in cellular migration and invasion. Thus, disruption 
of their binding, either by reducing the levels of intracellular S100A7 with siRNA or by  the 
use of a membrane permeable TAT peptide conjugated to the C-terminal β6 residues 
containing the S100A7 binding sites, were both sufficient to inhibit αvβ6-dependent invasion 
in vitro [146]. 
 Important evidence supporting a role for S100A7 in promoting migration/invasion in 
vivo has also recently come to light through the use of the mouse paralog of S100A7, 
mS100a7a15 inducibly expressed in a transgenic mouse model and aggressive MVT-1 cells 
(derived from mice doubly transgenic for MMTV-c-Myc and MMTV-VEGF)[142,149]. 
Induction of high levels of mS100a7a15 in the transgenic animal was shown to increase 
dramatically the metastatic abilities of MVT-1 cells, resulting in the formation of secondary 
lesions in the lung. The direct mechanisms are not fully understood, but changes in the 
expression patterns of molecules such as MMP-9 and vascular endothelial growth factor 
(VEGF) in MVT-1 cells and/or the recruitment of macrophages to the sites of the primary 
lesion have been put forward as possible explanations [142]. 
 S100A7 has also been shown to act as a potential tumor suppressor and to inhibit 
cellular migration when expressed. For instance, overexpression of S100A7 was found to 
decrease significantly the chemotactic and migratory abilities of MCF7 and T47D breast 
cancer cell lines through a possible loss of lamellipodia [150]. Further analysis suggests that 
high expression of S100A7 down-regulates the -catenin/TCF4 pathway through an 
enhanced interaction of β-catenin and E-cadherin. Supporting the role of S100A7 as an 
inhibitor of cellular migration in cancer cells, further work with MDAMB468 breast cancer 
cell line demonstrated that down-regulation of S100A7, using a specific short hairpin RNA, 
resulted in a reproducible and consistent increase in cell motility and invasion in Matrigel-
lined chambers [151]. In this work, S100A7’s ability to regulate the expression of MMP-13 
and VEGF were advanced as potential mechanisms towards increasing motility in vitro.  
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S100A8 and S100A9: 
High levels of S100A8 and S100A9 proteins have been correlated with increased cellular 
motility and migration through biomembranes using different cultured cell systems, including 
leukocytes (recently reviewed in Goyette and Geczy [152]). These properties have been 
linked to both intracellular and extracellular roles for such proteins, using methods to regulate 
their concentration in cells or through the use of purified proteins or specific antibodies to 
enhance or counteract their functions, respectively. For instance, the presence of either 
recombinant S100A8 or S100A9 proteins in the medium (10
-12
 to 10
-9
M) was sufficient to 
activate neutrophils and induce a significantly raised chemotactic response in modified 
Boyden chambers, whilst the sole addition of antibodies raised against either one was also 
enough to prevent cellular invasion in vitro [153]. It is, however, important to relate these 
findings to a potential physiological role. Interestingly, concentrations of S100A8 and 
S100A9 in human serum are found to be in the nanomolar range [154], concentrations that 
are therefore much higher than the ones used in this study. It is further thought that higher 
levels of S100A8/A9 found at sites of inflammatory conditions [155-157] are, at least in part, 
responsible for the subsequent infiltration of neutrophils and activation of 
monocyte/macrophages, casting some doubt on the biological relevance of this in vitro data.   
 Other cell types are similarly affected by the presence of S100A8 and S100A9 in their 
extracellular environment. Thus HUVEC endothelial cells and PNT1A SV-40 immortalised 
normal human prostate cells in culture can penetrate through transwell membranes and/or 
migrate more efficiently on addition of purified S100A8 or S100A9 at concentrations in the 
micromolar range or obtained from conditioned media  [158-160]. This extracellular motility 
enhancing property is also conserved in some tumor cells, since addition of S100A8 or 
S100A9 to the medium provoked dramatic increases in migration of the rectal cancer cell line 
SW837 [161]. Furthermore, genomic ablation of S100A9 resulted in mice that had 
significantly decreased tumor incidences and reduced rates of metastasis following 
spontaneous tumor formation using or after ectopic injection of MC38 colon tumor cells 
[162], importantly supporting a role for this protein in motility and invasion of cancer cells in 
vivo. Different cellular receptors have now been highlighted as potential mediators of the 
extracellular S100A8-S100A9-dependent migration. Indeed evidence indicates that the 
S100A8/A9 protein dimers interact or colocalise with RAGE at the surface of colon, prostate 
and melanoma tumor cell lines [162,160,163]. Their colocalisation appears to be important 
for the enhancement of cell motility, since addition of RAGE antibody to murine metastatic 
melanoma B16F10 cells in culture is sufficient to counteract the migration-promoting effects 
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of picomolar concentrations of either S100A8 or S100A9  [163]. In other cells from non-
pathophysiological conditions, S100A9 at concentrations around 10
-7 
M is thought to promote 
human neutrophil chemotaxis through activation of the β2 integrin, Mac-1 receptor [164]. 
S100A9 (but not S100A8) can also interact specifically with the cell surface glycoprotein 
EMMPRIN (BASIGIN) and that high expression of this receptor is required to induce the 
migration of  melanoma cells, possibly through increases in MMP1 expression [165].  
 Intracellular molecules can also be specifically regulated in the presence of high 
micromolar levels of extracellular S100A8/S100A9 in cultured cells.  As such, treatment of 
cells with recombinant S100A8 resulted in dramatic changes in the actin polymerisation of 
human polymorphonuclear neutrophils (PMN) and WEHI 265 monocytoid cells, where F-
actin accumulation within pseudopodia was profoundly affected, possibly explaining the 
changes observed in cell shape and cell size [166]. Lewis Lung carcinoma cells treated with 
recombinant S100A8 or S100A9 proteins ranging from 10
-13
 to 10
-8
M also demonstrated 
significant morphological rearrangements with the formation of large cellular protrusions, 
possibly pseudopodia and invadopodia, which were dependent upon activation of mitogen-
activated protein kinase p38 [167]. Supporting this observation, the phosphorylation of the 
complex S100A8/S100A9 by p38 was shown to regulate its association with F-actin in vitro. 
This colocalisation could also be seen in cultured human neutrophils in the actin-rich regions 
of lamellipodia following stimulation with the strong chemoattractant fMLP [168]. Others, 
however, have suggested that S100A9-deficient PMN cells demonstrated abnormal polarised 
cell shape with strong accumulation of F-actin in pseudopods [169], therefore blurring 
somewhat the true roles of these proteins in actin remodelling. 
 Besides these changes induced by extracellular levels of the S100A8/S100A9 
discussed so far, other evidence suggests that the intracellular localised S100A8/S100A9 
pools can equally affect these proteins’ functions. Thus, interactions of the S100A8/S100A9 
complex with the microtubule network and intermediate filaments have been reported in 
cultured hematopoietic cells [170,171].  The direct interaction between tubulin and 
S100A8/S100A9 takes place in a calcium-dependent manner, resulting in an increase in the 
number and stability of tubulin filaments [170] with follow-on studies demonstrating that the 
formation of a (S100A8/S100A9)2 tetramer is essential for the promoting effects of these 
proteins on microtubule formation [172]. Cell work has further demonstrated that S100A9-
deficient phagocytes contain lower levels of polymerised microtubule filaments, an 
observation that may explain differences in migratory properties seen in such cell 
backgrounds [170]. Neutrophils isolated from S100A9-deficient mice also showed migration 
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rates that were lower than those from wild-type mice, particularly when they were stimulated 
with Interleukin IL-8; their ability to cover greater distances than unstimulated neutrophils 
was also reduced [169]. In contrast another study demonstrated that treatment of the same 
S100A9 null cells with other chemokines (FMLP, KC and MIP-2) did not result in any 
significant change in chemotaxis [173].    
S100A9 has been shown to be important for transendothelial migration of 
granulocytes following activation by arsenite, since S100A9 -/- cells showed no acceleration 
of their migratory properties when compared to their wild type counterparts [170]. 
Importantly such inhibition of neutrophil/granulocyte motility could also be observed in vivo. 
Thus when LPS was injected into the murine air pouch, it resulted in a rapid accumulation of 
neutrophils. However this recruitment of neutrophils could be efficiently prevented with an 
antibody to S100A8, indicating the importance of extracellular S100A8 in neutrophil 
accumulation [174]. S100A9 is also a vital regulator of granulocyte migration in a wound 
healing model, since these cells from the knock-out mice demonstrated severe reduction in 
their ability to infiltrate neighbouring tissues and resulted ultimately in a decelerated closure 
of skin wounds when compared to control animals [170]. 
 
S100A10 
S100A10 has recently been shown to regulate macrophage invasion both in vivo and in vitro.  
Thus when macrophages from S100A10-/- transgenic mice were isolated, they exhibited a 
dramatic reduction in invasion through the Matrigel barrier in a Boyden chamber, but no 
changes in overall migration [175]. Similar observations were made when studying the 
recruitment of leukocytes into intraperitoneal cavities, with a much lower number of the 
S100A10-/- cells able to reach such cavities, highlighting an important regulatory role for 
S100A10 in such infiltration in vivo.  
 Changes in expression of S100A10 by these macrophages have also highlighted a 
crucial role for S100A10 in carcinogenesis in vivo. Thus, tumor growth from T241 
fibrosarcomas or murine Lewis lung carcinomas was significantly impaired in another study 
using S100A10-/- null mice due to a loss of macrophage recruitment at the tumor site [176].  
However, it is thought that some of the cancer-promoting abilities of S100A10 may, 
in fact, be due to another mechanism. Thus, upregulation of intracellular S100A10 expression 
has been demonstrated in high grade and basal-type breast cancers compared to low grade 
and non-basal types, suggesting a possible role for this protein in the migratory and/or 
invasion steps required for dissemination of the tumor cells [177]. Such a suggestion has been 
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further strengthened by reports showing that S100A10 can play a role during invasion and 
migration in vitro, although there is some uncertainty in the latter. Thus when the level of 
intracellular S100A10 was knocked down, invasion of colorectal cancer cells and human 
HT1080 fibrosarcoma cells through Matrigel membranes in the presence of plasminogen was 
reduced, but surprisingly cellular migration was unaffected [178,179]. Two other independent 
reports have since presented the ideas that S100A10 plays an essential role during cell 
motility at least in vitro, since down regulation of its intracellular expression in a human 
epithelial squamous carcinoma cell line and in aggressive lung cancer cells led to a 
significant reduction in cellular migration using the scratch wound assay [180,181]. 
The ability of S100A10 to remodel the actin cytoskeleton is not novel. Initially 
S100A10 was shown associated in a heterotetrameric complex with annexin 2 at the plasma 
membrane [182,183]. Subsequent experiments highlighted the ability of this complex to 
bundle actin filaments in a calcium-dependent manner [184,185]. S100A10 can play a major 
role in overall actin remodelling and motility in a human epithelial squamous carcinoma cell 
line, since down-regulation of its expression using specific siRNA led to a disorganisation of 
actin filaments and impaired cellular migration when using the in vitro scratch wound assay 
[180]. The Rho GTPase-activating protein DLC1 protein interacts with S100A10. This 
interaction recruits S100A10 away from annexin 2 and targets it to ubiquitin-dependent 
degradation, therefore reducing its steady state level, leading to lower cell migration and 
invasion of the aggressive lung cancer cell lines in vitro [181].  
 
 
S100A11 
The S100A11 protein has been linked to changes in cellular motility and cytoskeletal 
reorganisation, as well as involvement in tumorigenesis, but a clear picture has not emerged  
(recently reviewed in [24]). Its overexpression is observed in a large variety of carcinomas, 
suggesting that S100A11 plays an important regulatory role in carcinogenesis and cell 
proliferation [124,186], whilst others suggest it possesses tumor suppressing abilities [187]. It 
is thought that its presence, whether intracellular or as a stimulus from the extracellular 
environment, as well as its actual subcellular location, may be responsible, at least in part, for 
the observed antagonist effects of the protein [188].   
 S100A11 has been demonstrated recently to promote cellular migration in response to 
cell treatment with hypoxia-induced mitogenic factor. Thus depleting levels of intracellular 
S100A11 using siRNA technology was sufficient to compromise significantly the migration 
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rates of smooth muscle cells following treatment with hypoxia-induced mitogenic factor, a 
protein that promotes cellular motility. This change in cellular motility also coincided with 
the translocation of S100A11 from the cytosol to the plasma membrane and the nucleus 
[189]. Changes in S100A11 subcellular location have also been reported following the 
formation of cell-cell contacts and have been linked to the phosphorylation status of the 
protein [187]. High expression of S100A11 has been demonstrated equally to lead to an 
increase in cell protrusions and pseudopodia, possibly through the control of actin 
organisation [187]. Supportive of these findings is the fact that S100A11 can interact with 
actin both in cultured cells and in the test tube and that their association is regulated by 
phosphorylation in response to cell-cell contacts, since phosphorylated S100A11 was found 
to occur in the nucleus [187]. Other analyses have demonstrated the interactions of S100A11 
with annexin 1 [190] and the annexin 2 receptor at the cell membrane. [189]. The 
consequences of these interactions on cellular motility remain to be elucidated. 
 
 
S100A12 
S100A12 is present in the myeloid cell lineage, since it is found in abundance in granulocytes 
[191] as well as monocytes [192,193] and lymphocytes [194] in human but is not expressed 
in mouse counterparts. Some of the biological functions related to S100A12 are mediated by 
its association with the RAGE receptor, at least in cultured cells [195], but other receptors 
such as those of the G-protein-coupled family may also be important [196].  Extracellular 
S100A12 can induce directional migration and chemotactic responsiveness of monocytes and 
neutrophils in vitro [193], however, it is not known whether these effects relate to 
physiological extracellular concentrations of S100A12. Furthermore, injection of S100A12 
intraperitoneally into mice led to increased recruitment of leukocytes at the site of 
administration, highlighting its potential role in regulating both migration and chemotaxis in 
vivo from the outside of a cell. However, since these cells may have expressed S100A8/9, 
which can also affect migration, these results may have be confounded by the presence of 
other active S100 proteins. 
The mechanisms whereby S100A12 promotes chemotaxis have not been clearly 
established. One of the key steps towards chemotaxis and migration from the blood to the 
inflammatory site is the adhesion of cells of the leukocyte lineage. S100A12 has been shown 
to promote monocyte, neutrophil and lymphocyte adhesion in vitro [195,193,197]. Such 
properties were, at least in part, due to activation and increased expression of the Mac-1 
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integrin [197], a molecule that can interact with fibrinogen and has equally been shown to be 
regulated by S100A9 [164]. 
 Other transmenbrane proteins that are activated by S100A12 are ICAM-1 and 
VCAM-1, as well as the RAGE analogue [195], and all of these may be important for 
leukocyte recruitment, at least in vitro. At the intracellular level, S100A12 can increase actin 
polymerisation, also associated with calcium flux in monocytoid cells [193].  
 
 
 
S100B 
The S100B protein is highly abundant in the brain, where it localises to astrocytes, and can be 
found both intracellularly and extracellularly, where it is believed to exert different biological 
roles. For example, it can induce severe changes in cellular proliferation, apoptosis and cell 
differentiation, through different pathways; these pathways have recently been reviewed [18] 
and will only be briefly discussed here with regard to their effects on cellular migration 
(effects on proliferation of myoblasts/lung adenocarcinoma cells and on differentiation of 
chondrocytes/myeloblasts are summarised in Table 2). 
Overall and to the best of our knowledge, S100B has been proven to be an important inducer 
of cell motility in most, if not all, cell systems used in vitro. A direct correlation between its 
expression and cellular migration has, however, remained elusive in vivo, except in disease 
states. Indeed mice where S100B expression has been ablated via gene targeting have 
demonstrated very little problematic physiological consequences and no clear changes in 
tissue structures of the brain [198]. High level expressions of S100B have been linked to 
carcinogenesis in vitro, particularly melanoma, as well as brain-derived astrocytomas and 
glioblastomas, where S100B is thought to induce cell proliferation through interaction with 
p53 [199].  
 It is now well accepted that one of the more direct regulatory effects of extracellular 
S100B, at micromolar concentrations, on cellular migration is promoted through its 
interaction with RAGE, both in cultured cells and in cell-free systems using purified proteins 
(see references herein and [200]). The cascades of signalling pathways activated by the 
coupling of these two proteins have, however, been shown to be different, depending on the 
type of cultured cells studied. For instance, in neurons, the S100B-RAGE complex has been 
linked to extension of neurite outgrowth in a Cdc42-Rac1 dependent manner [201], whilst in 
murine microglia and vascular smooth muscle cells, this effect is promoted by the activation 
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of a myriad of effectors, including Src kinase [202,203]. The downstream effectors following 
on were, however, not identical, some activating the Ras pathway, whilst the MAPKs 
(p38MAPK and ERK1/2) and transcription factor NF-kB were activated in others. The use of 
inhibitors directed towards either Src or p38/MEK kinase have clearly established their 
importance in both vascular smooth muscle cell [203] and Schwann cell migration in vitro 
[204].  
 Besides the extracellular role of S100B through the RAGE receptor, recent reports 
have highlighted other possible pathways where S100B may encourage cellular motility in 
vitro. A reduction in the levels of S100B in astrocytoma cell lines, obtained by siRNA 
technology, resulted in reduced migration, possibly through the rapid collapse of F-actin at 
the plasma membrane. Such changes may to be due to the loss in intracellular levels of the 
S100B protein, since addition of extracellular recombinant S100B, in the nanomolar range, 
was not sufficient to reverse these phenotypic changes [123]. Similar observations regarding 
S100B expression and motility were also observed in cancer cell lines. When the expression 
of S100B in non-small cell lung cancer PC14 cells was altered following either transfection 
with episomal plasmids or with siRNA, it affected cellular migration in transwell assays as 
well as invasion using Boyden chambers. Thus, increased levels of S100B could promote 
motility, whereas reducing its levels correlated with a significant reduction in cell movement 
in vitro [205,206]. In these two cases, it is unclear whether the phenotypic changes were 
preferentially due to intracellular or extracellular pools of the S100B proteins. 
 Interactions of S100B with numerous components of the cytoskeleton have also been 
reported.  Using purified proteins, S100B has been shown to interact directly with 
components of the actin cytoskeleton such as CapZ [207] and caldesmon [208], the 
microtubule protein tubulin [209] and tau [210]. Recent studies have reported the 
colocalisation of S100B with different cytoskeletal architectures [211,212], but proof of their 
interactions in living cells has been more difficult. The direct biological implications of such 
subcellular locations have only been linked to motility through coincidental observations so 
far.  For instance, the RhoA/ROCK pathway has been put forward as a possible mediator of 
cellular migration activated by S100B [123], whilst similarly, the formin protein, diaphanous-
1, is also recruited and is essential for any observed migratory enhancement produced by 
S100B [202].   
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S100P 
As with some of the other S100 proteins discussed above, the role of S100P in neoplastic 
progression has generated much interest over the last decade [213,214] and was recently 
reviewed in Gibadulinova et al. [215]. S100P expression is, however, not restricted to 
carcinogenesis, since it can be seen readily in most human tissues, particularly in the placenta 
and oesophagus [216]. The direct physiological implication of its expression is currently 
unclear, although a recent investigation has proposed a role for S100P in endometrial 
implantation [217] and the regulation of its expression in the endometrium has been 
demonstrated further to vary according to the ovarian cycle [70]. Similarly, an emerging 
consensus has now clearly linked S100P expression with promoting cellular motility and 
invasion in numerous disease states, such as cancer (discussed below) and endometriosis, but 
the direct demonstration that the protein retains similar properties in healthy cells has so far, 
and to the best of our knowledge, not been reported. It is therefore through studies of 
different carcinomas, in animals, tissues and at the cellular level, that most information on 
this protein has been acquired, sometimes through coincidental observations of the aberrant 
levels of S100P and the carcinogenic and metastatic nature of the tumors studied [218]. 
Recent work in culture has indeed demonstrated that direct ectopic overexpression of 
intracellular S100P is sufficient to promote cellular motility of rat mammary and human 
HeLa cells [219], a human lung squamous carcinoma cell line HTB-58 [220], human 
pancreatic carcinoma cell lines [221] and human breast carcinoma cell lines [222]. The 
reverse experiments  also appear to hold true and specifically reducing the aberrantly high 
levels of intracellular S100P in cancer cell lines, obtained from the colon [223,224] and the 
pancreas [225,221], reduce both their migratory and invasive properties in vitro. Importantly 
direct evidence has also been presented in animal models, where inducing high S100P 
expression is sufficient to promote carcinogenesis and metastasis [225,213,221], whilst down 
regulating its level is enough to impede normally highly malignant cells from forming 
secondary lesions [223]. 
 The molecular mechanisms for the S100P-dependent effects on cellular migration and 
invasion have been the focus of different investigations, generating different outcomes, 
depending on the cultured cell types used. Cellular targets that could contribute to such 
phenotypic changes include intracellular components of the actin cytoskeleton, and over the 
years, S100P has been reported to affect directly the properties of a number of proteins 
 24 
 
involved in remodelling of the actomyosin network. The direct interaction between ezrin and 
S100P was first demonstrated ex vitro through affinity chromatography. This binding resulted 
in the cosedimentation of the complex along with F-actin. Further in vitro studies on the 
human lung squamous carcinoma cell line HTB-58 suggested a correlative link between 
S100P-ezrin interaction and transendothelial migration, in that ectopic expression of a S100P 
mutant, incapable of binding to ezrin, was similarly unable to promote cellular invasion 
which was observed when expressing the wild type counterpart [220]. Another actin regulator 
IQGAP1, which is thought to promote actin reorganisation through the Cdc42 and Rac1 
pathways can also interact with high affinity with S100P in pull-down, co-
immunoprecipitation and surface plasmon resonance experiments (Kd=0.2M)  [226]. The 
biological consequences of their binding on migration is not clear, since expressing S100P 
appeared not to induce significant changes in the overall actin organisation of HeLa cells 
(although no actual staining was provided)  and no data was given relating to their migratory 
properties.  
 In contrast, upregulating intracellular S100P expression in other cancer cell lines, 
such as pancreatic, Panc-1 and colon, LS174T cells has resulted in significant changes in 
cellular morphology and cytoskeletal organisation along with enhanced cellular migration 
[227,224], suggesting that S100P expression may induce different cell specific phenotypes. 
Indeed, ectopic expression of S100P in Panc-1 cells was found to correlate with the down 
regulation of several cytokeratins, but a robust phosphorylation level of cofilin along with an 
increase in S100A6 and cathepsin D proteins. The latter was further shown to be, at least in 
part, responsible for the invasive abilities of the S100P-expressing cells. Reducing S100P 
levels in colon LS174T cells by shRNA technology, resulted in severe abrogation of cellular 
protrusions (referred to by the authors as invadopodia structures) and reduced cell motility in 
vitro [224]. 
 In our hands, and using an inducible system, intracellular S100P expression was 
found to affect dramatically F-actin organisation in cultured rat mammary and HeLa cells, 
resulting in a severe disruption of the stress fibers stretching through the cytoplasm [219]. 
This loss in actin filaments was also shown to lead to a dramatic reduction in focal adhesion 
formation and stability. Such effects were demonstrated to be caused, at least in part, by 
direct interaction of S100P with the non-muscle myosin IIA isoform ex vitro and in vitro, 
suggesting that, as with S100A4, S100P expression could disassemble the myosin IIA 
network, resulting in possible loss of stress fiber contractility and reduced maturation and 
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formation of focal adhesions. Such changes would, in turn, result in increased cellular 
motility, a mechanism that was supported by experiments in which either down-regulation of 
myosin IIA or vinculin using siRNA technology, resulted in a similar non S100P-dependent 
increase in motility in vitro. 
However extracellular targets for S100P have also been identified as important inducers of 
some of its migratory activities in vitro, suggesting that it may also have physiological roles 
outside the cell. In support of this argument, S100P has been shown to be secreted from 
pancreatic Panc-1 cell lines where it activates RAGE, resulting in increased cell proliferation 
[221]. The wild type Panc-1 cells also  acquired migratory and invasive abilities through the 
addition of recombinant S100P proteins in the nanomolar range, although no quantification of 
the motility was provided and a direct connection between S100P-RAGE was not presented 
[221]. Independently, migration of SW480 colon cancer cells through the Transwell motility 
assay was found to be significantly improved following treatment with nanomolar 
concentration of recombinant S100P protein [228], whilst the addition of an antagonist of the 
RAGE receptors blocked this effect, suggesting a possible role for S100P-RAGE inn cellular 
motility, possibly through the ERK1/2 and NF-kB pathways, at least in vitro. 
 
 
2. S100 proteins, cellular migration and diseases  
 
Through decades of research, the family of S100 proteins has been linked to numerous 
pathologic conditions which have been comprehensively reviewed [229,84,230-232] and 
other reviews herein, to cite just a few). A few points related to specific S100 proteins, 
migratory properties and diseases will be succinctly summarised here.  
 Although the large majority of S100 proteins have been reported to be associated with 
cellular motility and to be involved, at least coincidentally, in a plethora of diseases, direct 
evidence has, to our knowledge, been reported unambiguously only in carcinogenesis/ 
metastasis and other “physiological” invasions, such as fibrosis, where they are usually 
considered to be relevant markers of disease progression [28,46,57,133,215]. 
 Intracellular expression of S100A4 (reviewed in Schneider et al. [84]) and to a lesser 
extent S100P [233,234], have now illustrated the possible transition of epithelial tumor cells 
to a more mesenchymal morphology. These, along with the expression of specific MMPs 
such as MMP-3, -9 and -13 can start to account for the increased motility and invasive 
properties respectively, seen during the steps of metastasis. Other concepts also support the 
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role of S100A4 and other S100 proteins, through a change in the tumor micro-environment, 
providing cues and stimuli that encourage outgrowth of overt metastases, in a series of events 
usually referred to as the metastatic niche [235,20]. Indeed, S100A4 expressing fibroblasts 
may be needed at tumor sites to facilitate carcinogenesis, possibly through release of 
extracellular S100A4 in the tumor environment, inducing local inflammation [236].  Through 
a reciprocal influence of tumor and stroma cells, this extracellular S100A4 may trigger pro-
metastatic cascades, involving the p53 protein and the down regulation of the pro-apoptotic 
bax, along with the angiogenesis inhibitor thrombospondin-1 and MMP-13, in tumor cells 
[237].  
 The establishment of the metastatic niche, in the context of S100A4, may also be 
encouraged by the recruitment of T cells and macrophages into the tumor microenvironment 
[238,239]. How extracellular S100A4 may contribute to such accumulation of myeloid cells 
is not clear, but both the chemotactic properties of the protein and its ability to promote 
cellular migration [81] may be considered as a prime driver of such a phenotype. In this 
context, other S100 proteins, such as S100A8 and S100A9 have also been implicated in 
tumor progression, regulating various processes during chronic inflammation [240]. Through 
their expression in many epithelial tumors and infiltrating myeloid cells [241], they may 
promote infiltration of immune cells within the tumor stroma, in a process that appears to be 
critical in tumor progression. However the direct molecular events taking place remain 
unclear, but could possibly be due to the S100A8/S100A9 dependent enhancement in 
leukocyte adhesion and migration discussed in earlier sections [169,153].   
S100A8/S100A9, along with S100A4. are also associated with other cellular invasive 
processes leading to fibrosis, mainly of the kidney and liver [242,243](see review by 
Schneider et al. [84]), where the mesenchymal cellular organisation and therefore cell 
motility appear to be essential.  This trait is mirrored by S100A6, and high levels of the 
protein are also observed in liver cirrhosis, biliaris and chronic renal disease [244,245]. 
Aberrant levels of S100A4 have also been linked to pulmonary disease, and transgenic mice 
expressing high levels of the protein develop severe pulmonary vascular obstructive disease 
and arterial hypertension [246,247]. Equally important is the involvement of extracellular 
S100A4 in the injured heart. In hypertrophic conditions, high expression of S100A4 by 
fibroblasts and invading macrophages and leucocytes is seen at the site of injury, possibly 
encouraging cardiac growth in the injured myocardium [248]. Aberrant levels of other S100 
proteins during heart disease are also seen. Indeed altered expression of S100A1 has been 
linked to heart failure and hypertension, and is associated with cardiac performance, blood 
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pressure regulation [249] and during perfusion recovery following femoral artery resections 
[30], as for arthritis and other diseases affecting the human articulate cartilage [250,251] 
along with other S100 family members (S100A1, S100A2, S100A4, S1008, S100A9, 
S100A11, and S100B). Whether these cardio-changing associations of S100 proteins are 
directly linked to migration events or to other cascading signalling pathways associated with 
the S100 proteins is unclear. Even more important to consider is whether their expression is 
seen as causal mechanisms for such progression or limited to correlative observations mainly 
linked by association. 
 A final thought should be given to the important contributions of the S100 proteins to 
the regulatory mechanisms of inflammation, some of which have been discussed earlier, but 
now revisited here.  S100A2 is a functional component in the immune response during 
periodontitis and may serve as a potential biomarker for periodontitis [252]. S100A7, initially 
identified as a protein up-regulated in inflamed hyperplastic psoriatic skin [253], has been 
linked to inflammation and hyperproliferation through differential expression profiling 
[254,23], where it is thought to promote anti-microbial activity [255,141]. Equally 
S100A8/S100A9 are released at the site of inflammation by phagocytes, monocytes, 
epithelial cells and endothelial cells [256], potentially acting as potent chemo-attractants in 
inflammatory processes and eliciting antimicrobial properties to various microbial pathogens 
[257]. Finally S100A4 appears also to be linked with inflammation resulting from microbial 
presence [251], but in this case, it does not possess direct bactericidal effects, but rather 
contributes to a reduction in bacterial accumulation at sites of infection, since the phagocytic 
capacity of ablated S100A4 leukocytes was impaired in the clearance of large amounts of 
Staphyloccocus aureus.  
 
 
3. Rationalisation of role of S100A4/S100P in one single system 
 
This review has shown that different S100 proteins and even the same S100 protein in 
different, largely in vitro cell systems, can cause either increases or decreases in one apparent 
cellular activity, that of cell migration/invasion, using a multitude of mechanisms to do so 
(Table 3).  So is it possible to rationalise these effects and mechanisms from our own 
experience of S100A4/S100P in just one complete in vitro and in vivo system, that of the 
mammary gland? 
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In the mammary gland itself, we have shown that S100A4 expression occurs not in 
the epithelial cells themselves, but in the epithelial stem cells at the leading edge of growing 
budded structures, which penetrate and invade the surrounding fatty stroma [71,258].  
S100A4 is also seen in myoepithelial cells, the smooth muscle-like cells which surround the 
epithelium and, in addition to stromal cells (e.g. endothelial cells, fibroblasts and 
lymphocytes), it also occurs extracellularly in insoluble structures resembling collagen/elastic 
fibres [74].  These results obtained in vivo were substantiated in our rat and human mammary 
cell lines in vitro, where S100A4 marked one of the first changes along the epithelial stem 
cell to myoepithelial-like cell lineage.  Intermediate cells in this lineage isolated from benign 
tumors could also produce skeletal muscle, cartilage and bone precursors when reintroduced 
into syngeneic rats in vivo [258-260].  Moreover, overexpression of the transgene for S100A4 
in and scrape-loaded addition of recombinant S100A4 to cultured rat mammary epithelial 
cells dramatically increased the production of elongated mesenchymal myoepithelial-like 
cells, the latter within 48 hours and there was no such effect upon addition of recombinant 
S100A4 without scrape loading [71].  These results establish a direct intracellular role for 
S100A4 in this process.  In addition, the reduction in levels of the miRNAs commonly 
associated with epithelial to mesenchymal change is also observed in our cell lines isolated 
from a carcinogen-induced malignant metastasizing tumor TMT-081 [71] compared to their 
benign counterparts [261]; the former but not the latter also overexpress S100A4.  These 
suppressor miRNAs include all 5 members of the miRNA-200 family and miR-205 and these 
miRNAs are often downregulated in highly invasive/metastatic breast and other cancers 
[262]. Our results suggest that one possible target for these suppressor miRNAs, either 
directly or indirectly, may be S100A4.  Thus the normal production of S100A4 in the 
mammary gland could possibly trigger a natural development process of epithelial to 
mesenchymal cell conversion.  This ability of S100A4 may help to explain the frequency of 
S100A4’s expression in malignant cells of aggressive breast cancers [60] that are also 
normally predisposed to invade surrounding tissues [73].   
The main cellular activity of Sl00A4/S100P in our hands is in stimulating cellular 
migration and not other cellular functions like cell proliferation [69].  Thus, direct 
overexpression of S100A4/S100P from transfected vectors caused rat mammary epithelial 
cells to migrate and invade through transwell membranes to invade local mammary tissues in 
vivo [69]  and then to disseminate from the primary tumor to distant organs, particularly the 
lungs in intact syngeneic rats [56,213]. These results in vitro and in vivo were fully 
corroborated by mice transgenic for both MMTV promoter-controlled neu and normally 
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expressing rat S100A4 [80]. Although the overall process occurs in several steps, S100A4 or 
S100P, seem capable of inducing all of them even in vivo.  The first step, that of cell 
migration, seems to occur via the intracellular pool in our S100P-inducible mammary cells.  
Thus addition of recombinant S100P to uninduced cells, even at high concentrations up to 
1μM failed to stimulate this change; upon induction little or no S100P was secreted (<2nM), 
well below the 100 nM reported to be required in other cell systems [221,228]; and addition 
of the RAGE neutralising antibody or blocking peptide did not inhibit cell migration upon 
induction of S100P [219].  Thus rapidly produced intracellular S100P is sufficient to 
stimulate cell migration in our inducible rat mammary cell systems. However, it has recently 
been reported that addition of 100 nM extracellular S100A4 to the same rat mammary cells 
also stimulates cell migration, but this enhancement requires cross-linking of S100A4 via 
transamidation to produce higher-molecular-weight aggregates that work at the cell surface to 
enhance cell migration [263]. Whether sufficiently high external concentrations of S100 
proteins are found in vivo is debatable, but since S100A4 [74] and S100P [213] are associated 
with insoluble extracellular structures in vivo, it is possible that insoluble aggregates could 
bind to cell surface receptors of whatever type and elicit a response.  Thus two different 
routes for stimulation of migration can be identified under appropriate conditions, one 
intracellular and one at the cell surface and therefore may arise through different mechanisms 
in the same cells. 
In the case of cellular migration produced by intracellular S100 proteins, most 
investigations reviewed herein implicate molecules in the cytoskeleton as key targets for the 
S100 proteins.  In our hands S100A4/S100P can bind preferentially to NMIIA directly  [101] 
and in cultured cells in vivo [115,219] with Kd’s in the nanomolar to submicromolar range, 
then unzipping the NMIIA/actin filaments [118], and thereby dissolving and reorganising 
focal adhesion sites [219] to permit changes in cellular filopodial projections [61] in order to 
provide the necessary motive force.  However, this is not the whole story, since S100 proteins 
including S100A4/S100P have been reported herein to interact with other intracellular 
molecules connected with the cytoskeleton and cell migration, some more weakly than others 
[101].  Although we have not followed up the S100P-ezrin interaction [220], in our hands 
S100P can also interact with α, β tubulins with affinities comparable to those with NMIIA, 
inhibit the rate of tubulin polymerisation and also stimulate migration [264].  These results 
suggest that at least one S100 family member can interact with more than one cytoskeletal 
target inside a cell to stimulate directly cell migration, and that it is their relatively unique 
dimeric structure [265] of the interacting domains [118] that permits such target promiscuity. 
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In the case of cellular migration produced by extracellular aggregates of S100 proteins, the 
jury is still out, although glycosaminoglycan (GAG) and integrin co-signalling pathways 
linked to activation of protein kinase C have been proposed to be responsible in our rat 
mammary cells [263]. 
One of the main problems with the whole field of S100 proteins and cell migration is 
the fact that certain S100 proteins can stimulate, while others can inhibit this cellular 
function, and some S100 members can even do both, depending on the cellular context 
(reviewed herein).  Our published results suggest a possible explanation in that some S100 
proteins, e.g. S100A1 and S100A2 could bind to S100A4 or S100P in cell-free and in 
cultured cells to form heterodimeric structures with higher affinity than that for self-
association of either S100A4 or Sl00P alone.  The formation of such heterodimers was also 
observed to compete away the homodimer interactions with cytoskeletal NMIIA and to 
inhibit S100A4 or S100P’s stimulatory effects on cell migration in Boyden chamber assays 
and most importantly on invasion and metastasis in vivo in our syngeneic rat mammary 
model system [31,266,267].  Thus it is possible that the relative concentrations of different 
S100 proteins govern how an exogenously-expressed Sl00 protein may function with respect 
to its target molecules inside the cell, and whether it stimulates or inhibits cell migration. 
As well as the inducible intracellular expression of S100P being capable of 
stimulating cell invasion through Matrigel, 100 nM of externally-added recombinant S100P 
stimulated cell invasion but not migration through the same gel [219].  Thus the mechanism 
of invasion in our cell systems, by contrast, would appear to be stimulatable by both 
intracellular and extracellular pools of S100A4/S100P.  Since the amount of S100A4/S100P 
secreted in a transfected cell would be insufficient, at least in our cellular systems, to 
stimulate cell invasion from outside the cell (e.g. via RAGE receptors), the most likely 
molecules responsible are proteases, either of the cathepsin or metalloproteinase type 
[225,237].  We have evidence that primitive MMPs are produced in Ras and S100A4 
overexpressing and invading optic nerve cells in transgenic fly larvae [268].   
However, as stated earlier, S100A4 probably also exists in vivo in multimeric forms 
outside the cell anchored to extracellular molecules such as the GAG syndecan-4 [263] .  The 
local concentrations may then be sufficiently high to enable such extracellular material 
released from host cells such as reactive myofibrobasts [58] and/or T lymphocytes [239] to 
stimulate cancer cell invasion. In this respect both S100A4 [259] and FGF2 [269] are 
secreted by the same cells intermediate between epithelial and myoepithelial-like cells and by 
the myoepithelial cells themselves in our rat mammary stem cell system in vitro by non-
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classical secretory pathways. That the latter molecule is bound to extracellular GAGs 
[270,271] may suggest that S100A4 is bound to similar extracellular structures in vivo. 
In addition to stimulating cancer cell migration/invasion, some S100 proteins have 
also been reported to stimulate migration/invasion of endothelial cells and neovascularisation 
of cancer cells in vivo (reviewed herein) at relatively high 100nM to micromolar 
concentrations.  The stimulation of invasion of the malignant cells and their 
neovascularisation may be attributable, in part, to S100A4/S100P produced by host cells in 
their vicinity.  Thus, the S100 proteins may not only support the local invasive growth of 
cells from the primary tumor, but also their expansive growth in distant metastases.  In this 
respect Sl00A4-transfected rat mammary cells can not only stimulate invasive growth in the 
primary tumor, but also dramatically enhance the number and size of lung colonies in 
syngeneic rats in vivo when introduced directly into the circulatory system via tail vein 
injections [272].  Both effects in vivo are abrogated by transfection of the cells with mutants 
of S100A4 that are incapable of binding to NMIIA and of stimulating cell migration in vitro 
[116,273].  Thus the S100 family of proteins may be relatively unique in being able to bind to 
several molecular targets associated with the cytoskeleton to stimulate cell migration at least 
in cultured cells.  These proteins can also work from outside the cell to stimulate cancer cell 
invasion and endothelial cell migration in vitro and for these purposes may be produced from 
reactive host cells, although the evidence for this is less secure in vivo.  Thus the 
intracellularly and extracellularly produced S100 proteins may work in concert but through 
different pathways, both to initiate the process of metastasis as well as to sustain 
migration/invasion of the metastatic lesions themselves. 
 
 
 
 
4. Concluding remarks 
 
  The vast diversity of S100 proteins and their protein activities, both intracellularly as 
well as in the extracellular spaces, has led scientists to discover a multitude of biological 
pathways where these proteins may play vital functions,  including cell motility, cell growth, 
and cell survival. Although the ablation of S100A8 gene highlights its essential function in 
vivo, targeted deletions of many of these S100 proteins in mice have been shown not to 
demonstrate any overt anomalies or adverse effects on the life of animals (S100A4, S100A9, 
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S100B), possibly because other S100 proteins can compensate for the loss of one family 
member.  However, all of these S100 proteins have been shown to be capable of regulating 
cellular migration and sometimes cell invasion, at least in vitro. Of course, the limitations of 
such techniques do not necessarily reflect biological relevance in vivo, as demonstrated for 
S100A8 and S100A9, which can induce significant changes in cell behaviour at low 
concentration in vitro without necessarily leading to similar changes in physiological 
conditions when present at much higher levels [155-157]. Most cell migration assays 
presented here rely on planar cellular migration, a process that is readily accepted by the 
scientifical community, but only rarely seen in a true physiological environment. It is now 
well accepted that cellular migration in vivo will result from the arrangement of different 
cellular organisations where both mesenchymal and amoeboid migrations will play a part, 
along with other three dimensional cellular protrusions such as invadopodia [137]. Similarly, 
studying penetration of the basal lamina, an important aspect of cellular invasion, is also one 
of the more challenging to recapitulate in vitro as it requires dynamic interaction between the 
invading cells, especially when considering collective migration, and host cells from 
neighbouring and distant tissues, as well as the basal lamina and extracellular matrix itself.  
Consequently, and although most S100 proteins have been shown to be capable of regulating 
cellular migration and sometimes cell invasion, at least in vitro, the direct consequences of 
their expression, or lack of, to explain such biological relevance have remained elusive.  
The direct correlation of some of the S100 factors and specific pathologic conditions have, 
however, highlighted their importance as markers, providing the scientific community with 
new molecules to use as potential drug targets or possible effectors of certain molecular 
pathways.  Throughout this review, we have aimed to present the cellular consequences of the 
regulated expression of the S100 proteins and the cytological changes observed. It is apparent 
that some consensus can be drawn from such observations, at least in cultured cells. First, it 
seems clear that all S100 proteins induce some changes in the actin cytoskeleton organisation, 
however, this observation is only sometimes corroborated with direct interactions with actin 
or actin binding proteins (Table 3). As such, only S100A1 and S100A4 have been reported to 
bind to purified actin filaments, whilst S100A6, S100B and S100P have been demonstrated to 
interact directly with actin binding proteins, in the form of tropomyosin, CapZ, caldesmon 
and myosin IIA/ezrin, respectively. The regulation of microtubule organisation or the cell 
surface activation of RAGE is also a property that can be seen in multiple S100 proteins and 
may also play a significant regulatory role in cell migration. Analysis of the predicted 
amphipathic patch in the hinge region (Fig. 1) and the C-terminal portion of the S100 proteins 
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[13,14] are thought to be the direct regulator for the specificity in binding to other target 
molecules, but no obvious homology or similarity could be drawn from their sequences, in 
view of the different cellular targets highlighted here.  
 Strikingly, expression of some of the S100 proteins is shown to induce conflicting 
results on motility depending on the cells used, even in vivo. For instance S100A4 promotes 
migration of numerous cell systems, except astrocytes where its presence appears to be 
detrimental for such phenotypes. Similarly S100A6 is seen to reduce motility in most 
somatic/physiological balanced cells but accelerates movement in cancer cell lines, whilst 
S100A7 studies produce contradictory phenotypes in different breast cancer cell lines. It is 
experimentally unclear at the current time why such contradictory observations have been 
reported, but speculative arguments have been provided in this work, in regards to S100A4 
and S100P expression to try to answer this conundrum. S100 proteins have also been shown 
to induce cellular response through different mechanisms and routes, i.e. 
extracellular/intracellular cascade of signalling that could also affect the pathways involved, 
depending on the concentration required to elicit such biological responses.  Although in 
some cases the concentration of recombinant S100 proteins added to the different cell 
systems are in line with the levels expected in the extracellular space, but potentially not the 
amount of proteins released in the medium, there are still unanswered questions related to the 
true functions and biological consequences of such factors in vivo. Similarly, numerous S100 
proteins have been shown to change cellular motility through activation of the RAGE 
pathway (Table 3). Yet homozygous deletion of RAGE in mice present no overt 
abnormalities in animal’s viability and fertility [274], highlighting again whether any of these 
observations are of physiological developmental relevance in vivo.  
 Knowing the cellular effectors of the S100 proteins remains an area of intense 
research and consequently some of these proteins, or the antagonists that counteract their 
cellular activities are slowly making their way into plans of therapeutic avenues. For instance, 
because of its role as a key regulator of cardiac performance, cardiomyopathies and heart 
failure, S100A1 based gene therapy is being developed for clinical trials [275]. For S100A4, 
the S100 protein most closely linked to cancer progression, inhibitors of its activities have 
been used to identify new ways to combat its invasion-inducing capability. The results of 
such early work has identified the anti-helminth drug, niclosamide and a specific S100A4 
antibody, as two molecules that have been demonstrated to inhibit S100A4 induced 
metastasis and stromal cell invasion, respectively [276,93], paving the way for the 
development of further anti-metastatic drugs with S100A4 as primary target.  
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Figure 1: S100 protein amino acid sequence alignment 
Amino acids sequences of S100 proteins were aligned with the EF-hands and central regions 
indicated (number 1-12 in the canonical EF-hand motif refers to the position of essential 
amino acids for the formation of the calcium-binding loop). All sequences are human and the 
accession numbers are S100A1, AAH14392.1;  
S100A2, EAW53305.1; S100A3, EAW53306.1; S100A4, CAG29341.1; S100A5, 
EAW53317.1; S100A6, EAW53326.1; S100A7, EAW53327.1; S100A8, EAW53330.1;  
S100A9, EAW53334.1; S100A10, NP002957.1; S100A11,  NP005611.1; S100A12, 
EAW53332.1; S100A13, CAA68188.1; S100A14, AAM19206.1; S100A15, AAO40033.1; 
S100A16, EAW53304.1; S100B, NP006263.1 ; S100G, EAW98916.1; S100P, EAW82384.1 
and S100Z, EAW95784.1. Sequences were aligned using the multalin sequence comparison 
program (http://multalin.toulouse.inra.fr/multalin/) and the resulting data shaded and 
presented using the boxshade integrated program 
(http://www.ch.embnet.org/software/BOX_form.html). 
 
 
Table 1: Sequence identity between the different S100 proteins 
Amino acid sequences of each S100 protein (figure 1) was analysed for homology (identity 
and similarity in brackets)) compared to all other members of the family. Highlighted in bold 
are the highest (S100A7 and S100A15) and lowest (S100A3 and S100A7) conservation seen 
between the different members. 
 
Table 2: Potential roles of S100 proteins in cellular proliferation and/or differentiation 
Summary of possible roles for S100 proteins in cellular proliferation and differentiation. 
 
Table 3: S100 expression and examples in cellular migration/invasion in vitro 
Summary of how the aberrantly regulated levels of S100 proteins affect cellular 
migration/invasion and the possible mechanisms involved. 
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(39) 
24 
(37) 
31 
(41) 
42 
(52) 
29 
(34) 
39 
(50) 
42 
(58) 
A5      42 
(52) 
22 
(34) 
25 
(42) 
28 
(43) 
24 
(37) 
29 
(43) 
31 
(43) 
31 
(39) 
18 
(38) 
23 
(34) 
25 
(36) 
35 
(48) 
24 
(36) 
31 
(44) 
36 
(54) 
A6       25 
(43) 
25 
(49) 
33 
(50) 
26 
(50) 
31 
(49) 
39 
(50) 
30 
(41) 
24 
(41) 
27 
(46) 
28 
(49) 
41 
(59) 
31 
(40) 
37 
(57) 
38 
(60) 
A7        24 
(34) 
25 
(42) 
21 
(34) 
31 
(42) 
24 
(42) 
20 
(35) 
18 
(32) 
95 
(95) 
28 
(40) 
23 
(41) 
23 
(33) 
25 
(40) 
25 
(42) 
A8         27 
(52) 
27 
(50) 
27 
(44) 
43 
(57) 
23 
(45) 
18 
(39) 
27 
(40) 
31 
(46) 
32 
(44) 
27 
(39) 
41 
(58) 
30 
(49) 
A9          25 
(42) 
29 
(42) 
38 
(47) 
26 
(38) 
27 
(36) 
22 
(38) 
21 
(43) 
31 
(43) 
21 
(34) 
30 
(43) 
30 
(47) 
A10           37 
(58) 
30 
(44) 
22 
(38) 
26 
(45) 
25 
(39) 
24 
(45) 
35 
(50) 
22 
(37) 
41 
(56) 
46 
(69) 
A11            31 
(44) 
32 
(43) 
22 
(33) 
32 
(43) 
24 
(36) 
30 
(47) 
26 
(35) 
35 
(51) 
30 
(52) 
A12             30 
(49) 
26 
(47) 
26 
(47) 
25 
(40) 
38 
(53) 
30 
(38) 
45 
(53) 
39 
(54) 
A13              36 
(58) 
21 
(38) 
30 
(43) 
23 
(42) 
27 
(36) 
25 
(42) 
25 
(44) 
A14               18 
(32) 
21 
(41) 
24 
(37) 
17 
(28) 
21 
(37) 
22 
(38) 
A15                28 
(42) 
23 
(40) 
21 
(31) 
27 
(41) 
24 
(40) 
A16                 25 
(42) 
23 
(33) 
25 
(44) 
28 
(47) 
B                  30 
(39) 
50 
(63) 
43 
(60) 
G                   35 
(49) 
39 
(54) 
P                    49 
(61) 
Z                     
Table 2: Potential roles of S100 proteins in cellular proliferation and/or differentiation  
Protein Cell types Possible cellular functions References 
S100A1 Neurons Cell proliferation [32] 
Chondrocytes Differentiation [212] 
S100A2 
 
Squamous carcinoma Cell Proliferation [44] 
Keratinocytes Differentiation [277] 
S100A4 
 
 
Thyroid/colorectal carcinoma 
Cardiac fibroblasts/ myocytes 
Cell proliferation [278,62] 
[279,248] 
Cardiac myocytes 
Neurons 
Differentiation [280] 
[281,282] 
S100A6 
 
Fibroblasts 
Osteoblasts 
Cell proliferation [128] 
[283] 
S100A7 
 
 
Endothelial cells 
Squamous carcinoma 
Cell proliferation [284] 
[285] 
Mammary epithelial cells Differentiation [286] 
S100A8/
S100A9 
 
 
Endothelial cells 
Keratinocytes 
Cell proliferation [159] 
[287] 
Keratinocytes 
Thyroid carcinoma 
Differentiation [287] 
[288] 
S100A11 Lung adenocarcinoma 
Keratinocytes 
Cell proliferation [289] 
[124,186] 
Keratinocytes Differentiation [290] 
S10A12 Hippocampal neurons Differentiation [291] 
S100B Myoblasts 
Lung adenocarcinoma 
Cell proliferation [292-294] 
[206,294] 
Chondrocytes 
myoblasts 
Differentiation [212] 
[293] 
S100P Fibroblasts 
Prostate carcinoma 
Pancreatic carcinoma 
Cell Proliferation [295] 
[296] 
[221] 
 
 
Table 3: S100 expression and examples in cellular migration/invasion in vitro  
 
Protein Level in regulation  Cell type and changes in motility/invasion Possible cellular mechanisms References 
S100A1 
 
Ablation in knockout mice 
 
Reduced  in  endothelial cells  
 
None provided 
 
[30] 
 
Up by overexpression  
 
No changes in breast adenoma cells 
Reduced in breast carcinoma cells 
None provided 
Antagonise S100A4 dimer 
formation 
[31] 
[31] 
S100A2 
 
 
 
 
 
Down by antisense technology 
 
Increased in head and neck squamous carcinoma cells 
 
F-actin polymerisation dynamics / 
RAGE activation 
 
[43] 
 
Down by shRNA/siRNA 
 
Reduced in non-small cell lung cancer cells 
Reduced in hepatocarcinoma cells  
 
 [51] 
[53] 
 
Up by exogenous addition 
 
Reduced in head and neck squamous carcinoma cells 
Increased in eosinophils 
 
cyclooxygenase-2 (Cox-2) 
None provided 
 
[44]  
[50] 
 
Up by overexpression 
 
Reduced in oral squamous carcinoma cell  
Increased in non-small cell lung carcinoma cell 
None provided 
 
[44] 
[52,51] 
S100A4 
 
 
Ablation in knockout mice 
 
Reduced in macrophages 
Increased in astrocytes 
Myosin IIA/actin overassembly 
None provided 
[81] 
[96] 
Down by shRNA/siRNA 
 
Increased in astrocytes 
 
MMP-9 and MT1-MMP regulation 
 
[95,96] 
 
Up by exogenous addition 
 
Increased in endothelial cells 
 
Increased in pulmonary artery smooth muscle cells 
 
Increased in fibroblasts 
Increased in T lymphocytes 
RAGE activation 
 
RAGE activation 
 
Fibronectin deposition 
None provided 
[90] 
 
[91,92] 
 
[17] 
[93] 
Up by overexpression Increased in non-small cell lung carcinoma cells Myosin IIA/actin overassembly [66] 
 Increased in esophageal squamous carcinoma cells 
Increased in colon carcinoma cells. 
Increased in breast carcinoma cells 
AKT/Slug signal pathway 
Wnt/β-catenin pathway inhibitor 
MyosinIIA/actin  
 
MMP13 regulation 
Rhotekin/Rho 
 
[67] 
[68] 
[56,86,116,61] 
 
[65] 
[102] 
S100A6 
 
 
Down by shRNA/siRNA 
 
 
 
Increased  in fibroblasts cells 
 
Increased  in osteosarcoma cells 
Decreased  in pancreatic carcinoma cells 
 
 
Actin/tropomyosin remodelling 
 
None provided 
Annexin II 
None provided 
 
[127] 
 
[129] 
[131] 
[132] 
 
Up by overexpression 
 
Reduced  in osteosarcoma cells None provided [130] 
S100A7 
 
 
 
Down by shRNA/siRNA 
 
 
 
 
Reduced in oral carcinoma cells 
Reduced in breast carcinoma cells 
 
Increased in breast carcinoma cells 
Integrin 6 subunit 
Jab1 interaction 
None provided 
MMP13/VEGF  
[146] 
[147] 
[148] 
[151] 
 
Up by exogenous addition 
 
Increased in macrophages 
Increased in leukocytes 
Increased in osteosarcoma cells 
 
RAGE activation 
RAGE activation 
RAGE activation 
 
[142] 
[141] 
[144] 
 
Up by overexpression 
 
Increased in squamous carcinoma cells 
Reduced in breast carcinoma cells 
 
RAGE activation 
-catenin/TCF4 pathway 
[143] 
[150] 
S100A8/
S100A9 
 
 
Ablation in knockout mice 
 
 
Reduced in neutrophils ( IL8 treatment) 
Reduced in phagocytes 
Reduced in granulocytes (arsenite treatment) 
 
None provided 
Microtubule organisation 
None provided 
 
[169] 
[170] 
[170] 
 
  
 
 
 
 
 
 
Up by exogenous addition 
 
 
Increased in neutrophils 
Increased in macrophages 
Increased in human umbilical vein endothelial cells 
 
Increased in melanoma cells (S100A9 only) 
 
Increased in lung carcinoma cells 
 
Integrin 2 subunit Mac1 activation 
None provided 
None provided 
EMMPRIN 
RAGE 
P38 dependant pseudopodia 
 
[153] 
 
[167] 
[159,158] 
[165] 
[163] 
[167] 
 
Up by overexpression 
 
Increased in prostate carcinoma cells 
 
MAP kinase/NF-B/RAGE 
 
[160] 
S100A10 Ablation in knockout mice 
 
Reduced in macrophages (migration unaffected )  Plasmin [175] 
 
Down by shRNA/siRNA 
 
Reduced in colorectal carcinoma  cells (migration 
unaffected) 
Reduced in fibrosarcoma cells (migration unaffected) 
Reduced in squamous carcinoma cells 
Reduced in lung carcinoma cells 
Plasmin 
 
Plasmin 
microfilament organisation 
Annexin II/DLCI interaction 
[178] 
 
[179] 
[180] 
[181] 
S100A11 Down by shRNA/siRNA 
 
Reduced in smooth muscle cells 
 
Annexin II [189] 
S10A12 Up by exogenous addition 
 
 
Increased in neutrophils 
Increased in monocytes 
None provided 
None provided 
[193] 
[193] 
S100B Down by shRNA/siRNA Reduced in astrocytoma cells  
Reduced in lung adenocarcinoma cells 
RhoA/ROCK/Microfilament  
None provided 
[123] 
[206] 
Up by exogenous addition 
 
Increased in microglia cells 
Increased in smooth muscle cells 
Increased in Schwann cells 
RAGE/Src/Diaphanous-1 
RAGE/Src 
RAGE/p38 
[202] 
[203] 
[204] 
Up by overexpression 
 
Increased in non-small cell lung carcinoma cells None provided 
 
[205] 
 
S100P Down by shRNA/siRNA 
 
Reduced in pancreatic carcinoma cells 
Reduced in pancreatic carcinoma cells 
None provided 
None provided 
[221] 
[225] 
  
Reduced in colon carcinoma cells 
Reduced in colon carcinoma cells 
Invadopodia 
None provided 
[224] 
[223] 
Up by exogenous addition 
 
Increased in colon carcinoma cells ERK1/2 /NF-B/RAGE [228] 
Up by overexpression 
 
Increased in breast and cervical cancer cells 
Increased in lung squamous carcinoma  cells 
Increased in pancreatic carcinoma cells 
Increased in pancreatic carcinoma cells 
Increased in breast carcinoma cells 
Myosin IIA 
Erzin interaction 
Cathepsin D 
RAGE 
None provided 
 
[219] 
[220] 
[227] 
[221] 
[222] 
 
 
